



International Translational and Regenerative Medicine Conference

April 25-27, 2018 Rome, Italy

Fingolimod (FTY720) as an Anti-Multiple Sclerosis Oral Ultimate Therapy

Sara T Alrashood¹, Fadilah S Aleanizy², FulwahAlqahtani², AhadAbushal³, Noor AlSalama³ and Ghada S Hassan⁴

¹Department of Pharmaceutical Chemistry, King Saud University, Saudi Arabia

²Department of Pharmaceutics, King Saud University, Saudi Arabia

³College of Pharmacy, King Saud University, Saudi Arabia

⁴Department of Medicinal Chemistry, Mansoura University, Egypt

Multiple Sclerosis (MS) is a chronic progressive autoimmune disease. It has complex symptoms and challenges. Patients suffer the most from the inconvenience and intolerability till the old injectable disease modifying therapies. Therefore our research is highlighting the scoop on the newly available treatment using the oral therapies proceeding from their chemical nature and structure to prove their superiority to the traditional ones in controlling MS progression. This can lead to an improvement in life quality for MS patients with the enhanced tolerability for oral drugs that is best achieved by using Fingolimod that is considered as the first approved oral drug for this disease.